- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02554006
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings (BATMAN)
Predischarge Bundle for Patients in Dual Antiplatelet Therapy to Minimize the Negative Impact of Nuisance Bleedings on Quality of Life: a Randomized Controlled Trial.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Recent studies suggest that bleeding complications have a strong influence on quality of life. During DAPT regimen bleeding complications occur from 5% to 15% of patients. Nuisance bleedings (BARC 1 bleeding) occur more frequently and show a strong influence on quality of life, depression, anxiety and compliance to the treatment.
The aim of the study is to establish if a specific counseling programme might minimize the negative quality of life impact of nuisance bleedings. A computer-generated list will be used to randomize patients in a 1:1 ratio, stratified by age, sex, renal failure and P2Y12 inhibitor, to either the bundle or the control group.
All patients randomized to the control group (standard of care) will receive education from physician regarding dual antiplatelet therapy (DAPT) as part of the routine discharge process.
All patients randomized to the bundle group will receive:
i) a 15-min visit by a member of the research team 24 h prior to the anticipated discharge day. During this visit, a core set of DAPT risks will be addressed. Advantages and side effects of DAPT will be described. The importance of compliance will be discussed. The correct management of side effects (especially BARC 1 bleedings) will be discussed.
ii) a 15-min visit by a member of the research team with a family member living near/with the patient. Advantages and side effects of DAPT will be described. The importance of compliance will be discussed. The correct management of side effects (especially BARC 1 bleedings) will be discussed.
iii) brochure describing advantages, side effects and management of dual antiplatelet therapy. Contemporaneously, the investigators of the study will contact directly by phone and/or mail the general practionnaire of the patient to describe and explain the same topics and the clinical problem of her patient.
iv) availability of phone number to discuss potential side effects of DAPT. In addition, the study coordinator of the study will contact two times by month the patient by phone to assess DAPT compliance and potential BARC 1 bleedings.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Ferrara
-
Cona, Ferrara, Italia, 44124
- University Hospital of Ferrara
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- signed written informed consent
- hospital admission for ischemic heart disease with clinical indication to coronary artery angiography
- percutaneous coronary intervention and drug eluting stent implantation
- indication to dual antiplatelet therapy for at least 6 months
Exclusion Criteria:
- oral anticoagulant therapy
- bleeding event in the 30 days before the enrolment
- planned surgery
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Altro: good clinical practice
all patients will receive education from physician regarding management of dual antiplatelet therapy as part of the routine discharge process
|
education from physician regarding dual antiplatelet therapy as part of the routine discharge process
Altri nomi:
|
Sperimentale: bundle group
patients assigned to the bundle group will receive visits and materials as described by the protocol (counseling)
|
visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
quality of life
Lasso di tempo: 1 month
|
quality of life assessment in each patient by EQ-5D questionnaire
|
1 month
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
emergency room admission
Lasso di tempo: 1 month
|
number of access to emergency room service for bleeding
|
1 month
|
general practitioner visit
Lasso di tempo: 1 month
|
number of access to general practitioner for bleeding
|
1 month
|
dyspnea occurrence
Lasso di tempo: 1 month
|
number of patients suffering dyspnoea stratified according P2Y12 inhibitors
|
1 month
|
bleeding academic research consortium (BARC) 2-3
Lasso di tempo: 1 month
|
occurrence of BARC 2-3 complications
|
1 month
|
bleeding academic research consortium (BARC) 1
Lasso di tempo: 1 month
|
occurrence of BARC 1 complications
|
1 month
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
ischemic adverse events
Lasso di tempo: 1 year
|
cumulative incidence of the following ischemic adverse events: cardiac death, myocardial infarction, transient ischemic attack/stroke
|
1 year
|
all-cause mortality
Lasso di tempo: 1 year
|
occurrence of all-cause death
|
1 year
|
BARC 1-3
Lasso di tempo: 1 year
|
occurrence of BARC1-3 complications
|
1 year
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 150595
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su good clinical practice
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); BC Children's Hospital Research... e altri collaboratoriNon ancora reclutamentoPratiche genitoriali | Pratiche di co-genitorialità | Comportamenti alimentari e dietetici del bambino | Attività fisica del bambino/Gioco attivo/Gioco all'aperto | Tempo sullo schermo del bambinoCanada
-
Equiti Food, LLCNational Institutes of Health (NIH); University of North Carolina, Chapel Hill; University of North Carolina, Greensboro e altri collaboratoriIscrizione su invito
-
University of ChicagoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completato
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Reclutamento
-
Marshall UniversityUniversity of Toronto; University of Southern DenmarkReclutamentoArtrosi, ginocchioStati Uniti
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoCompletatoDisturbo depressivo maggioreCanada
-
University Hospital, RouenCompletato
-
Swiss Group for Clinical Cancer ResearchImmunophotonics, Inc.ReclutamentoTumori solidi avanzatiSvizzera
-
Mead Johnson NutritionCompletatoNeonati a termine sani alimentati esclusivamente con latte artificialeStati Uniti
-
University of NottinghamEnhanced Recovery After Surgery Group (part of ESPEN)Completato